BioMarin Pharmaceutical (BMRN) News
NASDAQ: BMRNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
54.80-0.095 (-0.17%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
BMRN news summary
We found 3 recent headlines mentioning BioMarin Pharmaceutical (BMRN): 1 in the past week and 1 in the past 30 days, most often from Nasdaq, PR Newswire. For price context, BMRN is down 0.17% at $54.80. The most recent story, "BioMarin Presents New Data Advancing Understanding of Achondroplasia and Hypochondroplasia Treatment at the American Society for Bone and Mineral Research Annual Meeting", was published by PR Newswire on Oct 9, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest BioMarin Pharmaceutical headlines
- BioMarin Presents New Data Advancing Understanding of Achondroplasia and Hypochondroplasia Treatment at the American Society for Bone and Mineral Research Annual MeetingNew analysis showcases impact of VOXZOGO® (vosoritide) in foramen magnum and craniocervical junction growth in children with achondroplasia, including infants SAN RAFAEL, Calif., Oct. 9, 2026…PR Newswire
- Weekly Buzz: IONS, MIST, BIIB, AZN Win Nods; TCRX, NVS Cut Jobs; OVID, VIR Data; REGN, PASG Deals(RTTNews) - This week's biotech roundup saw a flurry of FDA and EU approvals across neurology, oncology, cardiology, and rare diseases, alongside new partnerships, trial readouts, and restructuring…NasdaqAPVO, ASND, AZN, BIIB
- Weekly Buzz: RARE, REGN Secure FDA Nod, BMRN Stikes Deal; HUMA, EYPT Face Trial Setbacks(RTTNews) - This week's global biopharma roundup captured a mix of regulatory approvals, strategic partnerships, acquisitions, and merger activity, alongside clinical trial breakthroughs and halts.…NasdaqALIT, ARGX, AZN, BMRN